Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EQ 101

Next Previous
Search
Drug Profile

EQ 101

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40; EQ-101

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioniz
  • Developer Bioniz; Equillium
  • Class Antineoplastics; Antivirals; Peptides; Skin disorder therapies
  • Mechanism of Action Interleukin 15 inhibitors; Interleukin 15 receptor antagonists; Interleukin 2 inhibitors; Interleukin 2 receptor antagonists; Interleukin 9 inhibitors; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Cutaneous T-cell lymphoma
  • Phase II Alopecia areata; Large granular lymphocytic leukaemia; T-cell leukaemia
  • No development reported Adult T-cell leukaemia-lymphoma; Tropical spastic paraparesis; Vitiligo

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for research development in Vitiligo in USA (IV, Injection)
  • 08 Aug 2024 Equillium plans a phase IIb trial for Alopecia areata in 2025 (SC)
  • 04 Jun 2024 Updated efficacy and adverse event data from a phase II trial in Alopecia areata released by Equillium

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top